Corticosteroid Therapy for Pneumocystis Jirovecii Pneumonia (PCP)

Primary Indication Criteria

The Centers for Disease Control and Prevention recommends corticosteroids for PCP patients with moderate-to-severe hypoxemia, defined as PaO₂ <70 mmHg or alveolar-arterial (A-a) gradient >35 mmHg on room air, and should be initiated within 72 hours of starting anti-Pneumocystis treatment 1, 2
The American Thoracic Society indicates that the specific physiologic thresholds that trigger corticosteroid use are PaO₂ <70 mmHg on room air 1, 2
The Infectious Diseases Society of America states that the alveolar-arterial oxygen gradient >35 mmHg on room air is also a criterion for corticosteroid use 1, 2

The National Institutes of Health recommends that corticosteroids provide clear mortality benefit in HIV-positive patients with moderate-to-severe PCP, although the strength of evidence varies by HIV status 1, 2
The Kidney Disease: Improving Global Outcomes guidelines recommend corticosteroids for moderate-to-severe PCP using the same criteria as HIV patients (PaO₂ <70 mmHg or A-a gradient >35 mmHg) in kidney transplant patients 2

The Centers for Disease Control and Prevention suggests a standard regimen of prednisone oral or methylprednisolone IV equivalent, with a dosage of 40 mg twice daily (or methylprednisolone 30 mg IV twice daily) for days 1-5 1
The American College of Chest Physicians recommends alternative pediatric/weight-based regimens, with a dosage of 1 mg/kg twice daily for days 1-5 1

The Infectious Diseases Society of America states that corticosteroids must be initiated within 72 hours of starting anti-Pneumocystis therapy to be effective 1

The European Respiratory Society recommends screening for active infections before initiating corticosteroids, as infection risk increases during treatment 3, 4
The American Society of Transplantation suggests that patients receiving ≥20 mg methylprednisolone (or equivalent) for ≥4 weeks require PCP prophylaxis 5, 6

The American Thoracic Society advises against using corticosteroids in viral pneumonia, particularly influenza, as meta-analyses show increased mortality with corticosteroid use in influenza pneumonia 7, 8, 6
The Infectious Diseases Society of America recommends aggressive screening for opportunistic infections in non-HIV patients with PCP in the setting of severe alcoholic hepatitis or other conditions requiring corticosteroids 3, 4

The American Society of Clinical Oncology recommends corticosteroids for moderate-to-severe PCP in transplant recipients, including kidney transplant patients, and hematologic malignancy patients, such as those with diffuse B-cell lymphoma 9, 10
In non-HIV immunocompromised patients with critical respiratory insufficiency due to PCP, adjunctive corticosteroids are not generally recommended and should only be considered on an individual basis 9, 10

The National Comprehensive Cancer Network recommends PCP prophylaxis after recovery, using TMP/SMX as first choice, for patients with a history of lymphoma 9, 10, 11
Consider prophylactic antibiotics for patients receiving ≥20 mg methylprednisolone equivalent for ≥4 weeks, as recommended by the Journal for ImmunoTherapy of Cancer 12
GI prophylaxis with proton pump inhibitor therapy is recommended for all patients with grade 2-4 pneumonitis receiving steroids, according to the Journal for ImmunoTherapy of Cancer 12

Monitor for secondary infections, as increased infection rates have been noted in steroid-treated PCP patients, and consider dual CMV/PCP infection, as recommended by the MMWR Recommendations and Reports 13
Monitor for fungal superinfection, and consider continued mold-active antifungal coverage, given the patient's lymphoma background 9, 10

The American Thoracic Society recommends that patients receiving corticosteroids for Pneumocystis jirovecii pneumonia should be monitored for hyperglycemia, which may require treatment, as it is a common adverse effect 14
The use of corticosteroids may increase the risk of secondary infections, and patients should be closely monitored for this potential complication 14
The American Journal of Respiratory and Critical Care Medicine reports that corticosteroid use may lead to higher rates of rehospitalization, emphasizing the need for careful patient management 15
The American College of Chest Physicians advises against the use of corticosteroids in viral pneumonia, particularly influenza, as it may increase mortality 15, 16, 14

The Infectious Diseases Society of America recommends that patients with severe Pneumocystis jirovecii pneumonia who are not HIV-infected may benefit from combination therapy with trimetoprim-sulfametoxazol, caspofungina, and corticosteroids, which may improve clinical response rates and reduce adverse events 15, 16